as a combination therapy for adults with HR+/HER2- advanced or metastatic breast cancer. The average price target represents a 14.89 change from the last price of 103.14. The average price target is 118.50 with a high forecast of 120.00 and a low forecast of 117.00. Low levels of white blood cells, known as neutrophils, and liver-related adverse events were among the most frequently cited and noteworthy adverse events. (14.89 Upside) Based on 3 Wall Street analysts offering 12 month price targets for Novartis in the last 3 months. About a third of HR+/HER2 early breast cancer patients with stage II and more than half with stage III experience cancer recurrence.Īccording to an interim readout, the CDK4/6 inhibitor with ET cut the risk of cancer recurrence by 25.2% compared to ET alone in a broad set of patients with HR+/HER2- early breast cancer.Īs for secondary efficacy endpoints, Kisqali and ET led to 26% and 28% risk reduction in distant disease-free survival and recurrence-free survival, respectively. More than 90% of breast cancer cases are in the early stage. View analysts price targets for NVS or view top-rated stocks among Wall Street analysts. The minimum target price for Novartis AG analysts is 108.75. Novartis AG stock forecasts are adjusted once a day based on the closing price of the previous trading day. This suggests that the stock has a possible downside of 16.0. The Novartis AG stock prediction results are shown below and presented as a graph, table and text information. On average, they predict the company's share price to reach 82.25 in the next year. This suggests that the stock has a possible downside of 14.5. On average, they expect the company's stock price to reach 82.25 in the next twelve months. Their NVS share price forecasts range from 70.00 to 90.00. The global study was designed to evaluate Kisqali with endocrine therapy (ET) against ET alone in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer. Their NVS share price forecasts range from 70.00 to 90.00. 11 Wall Street research analysts have issued twelve-month target prices for Novartis' stock. JHVEPhoto/iStock Editorial via Getty ImagesĪnnouncing data from its pivotal study NATALEE, Novartis ( NYSE: NVS) announced Friday that its oral breast cancer therapy Kisqali as a combination regimen lowered the risk of cancer recurrence by 25% in certain patients with early breast cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |